Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
about
Use of fibrates in the metabolic syndrome: A reviewThe metabolic vascular syndrome - guide to an individualized treatmentNon-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD.Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.Third universal definition of myocardial infarction.Do diabetic patients with acute coronary syndromes have a higher threshold for ischemic pain?Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) studyIs silent myocardial infarction more common in women with type 2 diabetes than in men?Cohort comparison study of cardiac disease and atherosclerotic burden in type 2 diabetic adults using whole body cardiovascular magnetic resonance imagingA rare long-term survival of the life-threatening trio: silent myocardial infarction complicated by ventricular septal rupture, type 2 diabetes mellitus and chronic bronchitisTherapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes modelsCardioprotective medication use and risk factor control among US adults with unrecognized myocardial infarction: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.Race and Sex Differences in the Incidence and Prognostic Significance of Silent Myocardial Infarction in the Atherosclerosis Risk in Communities (ARIC) Study.Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 DiabAtherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study.Characteristics of the Relationship of Kidney Dysfunction with Cardiovascular Disease in High Risk Patients with Diabetes.Fenofibrate and metabolic syndrome.Fenofibrate in the treatment of dyslipidemia associated with HIV infection.AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes.Summarizing the FIELD study: lessons from a 'negative' trial.Does diabetes always confer coronary heart disease risk equivalent to a prior myocardial infarction?: implications for prevention.Admission glycaemia and its association with acute coronary syndrome in Emergency Department patients with chest pain.Third universal definition of myocardial infarction
P2860
Q26765234-B83EE54F-539D-44D9-A167-B4A7EC2429F5Q26767142-96D5C387-5EED-4519-8D4A-F6CFCF54F6C4Q33901914-1995D52D-50C3-417A-88D7-94AFD555F1C6Q33933474-4569F400-E330-499D-B9E7-DBF3FFD4BDA9Q34295914-AD213BE2-8EF6-4F65-AA9D-205F8B9644C0Q34319890-29542C7D-5C03-4B0B-ACFE-E34C037DD3B1Q35043302-8713AF0B-5100-4FD6-9AD0-CDBE0DFE12B2Q35947085-22A4AE7A-2594-47C8-9C07-C8A02D44C0C8Q36071862-B928E272-970F-433D-B7CD-29358DBDD01CQ36138227-E550DEBA-B64C-406C-AA22-919940CF1F32Q36477286-8B887B83-BE07-4995-A835-320B75F2D41CQ36601370-84BFE81C-F6E7-4F41-8FB4-08E5C1EE99D4Q36957797-642E9962-CB44-4F66-BEF3-316712405157Q36982097-A2B5F8AF-3C9D-436D-A5DE-69431979F1AAQ37119482-8D7AA676-20E8-4750-A9B2-DD3F159BB2C0Q37418843-CB348D82-19CD-45D4-9B1E-4745ADC35EF4Q37612824-967EF4B8-B1DB-490F-964F-581CC50C4F2DQ37770249-07E58FF0-D675-4453-BE7B-4C6653A757A0Q37851958-BCA1A0EB-BFBE-4FAC-AEAE-93E322C37A09Q38020453-6F84B56D-B0DE-4551-97D3-3AE40A322C71Q38160901-EA27E9B4-7109-4F55-8327-BC5BB17E26FCQ42613490-225A3713-B1A6-4450-B6EE-01A7AF47BD8AQ51313686-20B13CC1-7EAA-40FA-B411-94A7EA6F8C10Q57314061-F49AA6B2-76E3-408F-84BF-06E3C0C31009
P2860
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Incidence and predictors of si ...... ing in Diabetes (FIELD) study.
@en
Incidence and predictors of si ...... and Event Lowering in Diabetes
@nl
type
label
Incidence and predictors of si ...... ing in Diabetes (FIELD) study.
@en
Incidence and predictors of si ...... and Event Lowering in Diabetes
@nl
prefLabel
Incidence and predictors of si ...... ing in Diabetes (FIELD) study.
@en
Incidence and predictors of si ...... and Event Lowering in Diabetes
@nl
P2093
P2860
P356
P1476
Incidence and predictors of si ...... ing in Diabetes (FIELD) study.
@en
P2093
Anthony C Keech
David C Burgess
David Hunt
Diana Zannino
Elizabeth Williamson
Raymond W Sy
Seppo Lehto
Stewart Mann
P2860
P356
10.1093/EURHEARTJ/EHP377
P577
2009-09-29T00:00:00Z